Silexion Therapeutics Corp (SLXNW)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-03-25

Key Insights

Silexion Therapeutics Corp, an emerging growth company, has removed Ilan Levin from its Board of Directors through a unanimous decision by the other Board members.
The company's ordinary shares and warrants are listed on the Nasdaq Stock Market, providing access to public capital markets.
The removal of a director is a significant event that may signal changes in the company's leadership or strategy, which could impact investors.

Insider Trading Filed: 2025-12-31

Key Insights

The reporting person, Amnon Peled, acquired 661 ordinary shares and 780 stock options of Silexion Therapeutics Corp (SLXNW), indicating insider investment and alignment with shareholders.
The stock options and restricted share units granted to the director vest on the first anniversary of the grant date, suggesting long-term incentives and commitment to the company's success.
The 1-for-15 reverse share split effected by the issuer on July 29, 2025 has been properly reflected in the reported share and option amounts, providing transparency.

Insider Trading Filed: 2025-12-31

Key Insights

Avner Lushi, a director of Silexion Therapeutics Corp, acquired 1,587 ordinary shares indirectly through the Guangzhou Sino-Israel Biotech Fund (GIBF), indicating continued investment in the company.
Lushi also holds 14,721 ordinary shares and 1,872 stock options indirectly through GIBF, suggesting his commitment to Silexion's long-term success.
The reported transactions include adjustments for a 1-for-15 reverse share split, reflecting corporate actions that may impact the company's capital structure.

Insider Trading Filed: 2025-12-31

Key Insights

The reporting person, Noy Shlomo, is a director of Silexion Therapeutics Corp (SLXN) and possesses shared voting and investment authority over securities held by Guangzhou Sino-Israel Biotech Fund (GIBF).
GIBF was granted 1,587 ordinary shares and 1,872 stock options by SLXN, which vest on the first anniversary of the grant date, subject to the reporting person's or Avner Lushi's continued service.
SLXN has undergone a series of reverse share splits, including 1-for-9 in November 2024 and 1-for-15 in July 2025, which have been reflected in the reported share and option holdings.

Insider Trading Filed: 2025-12-31

Key Insights

Insider Ruth Alon has been granted 794 RSUs by Silexion Therapeutics Corp, vesting in 1 year, indicating potential positive sentiment and alignment with long-term shareholder interests.
Silexion Therapeutics Corp has undergone a 1-for-15 reverse share split, which may impact the stock price and trading liquidity.
The reporting person has also disposed of 403 ordinary shares, which could signal a shift in their ownership position.

Insider Trading Filed: 2025-12-31

Key Insights

Dror Yosef Abramov, a director of Silexion Therapeutics Corp, acquired 794 ordinary shares of the company through a restricted stock unit grant, indicating his continued commitment to and confidence in the firm.
Abramov also holds 935 stock options to purchase ordinary shares, which have been adjusted to account for the company's recent 1-for-15 reverse share split, further aligning his interests with those of Silexion's shareholders.
The filing also discloses that Abramov previously held 295 ordinary shares, which have been adjusted downward to reflect the reverse splits, suggesting a stable insider ownership position.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.